TriSalus Life Sciences Inc. (TLSI) is a Healthcare · Medical Devices company listed on NASDAQ. Price $5.10 (+4.08%), Market cap $0.16B, 52-week low–high $2.52 ~ $7.50.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational i
Financial statements, price targets, institutional (13F) holdings and related news for TriSalus Life Sciences Inc. are updated in real time on BlackAll Trade.
TriSalus Life Sciences Inc. trades at $5.10 (+4.08%). Real-time quotes and charts are available on BlackAll Trade.
TriSalus Life Sciences Inc. has a market cap of about $0.16B.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with dif